Clinical Trials Logo

ASC-US clinical trials

View clinical trials related to ASC-US.

Filter by:
  • None
  • Page 1

NCT ID: NCT05808816 Recruiting - HPV Infection Clinical Trials

"Lactobacillus Crispatus M247, LSIL and Microbiota"

Start date: June 16, 2021
Phase: Phase 4
Study type: Interventional

Patients affected by ASC-US/ low-grade HPV cervical lesions will be randomly assigned to treatment arm vs control arm. The treatment arm will include the characterization of the vaginal microbiota at enrollment (T0), 4 months of oral treatment with Lactobacillus Crispatus M 247 (1 buccal stick Die), characterization of the vaginal microbiota at 1 month post treatment (T5 m). The vaginal microbiota will be evaluated by Danagene microbiome vaginal DNA KIT-XMICROGem (XBIOGem) test, with amplification of the variable regions of the 16S ribosomal RNA gene, using the MICROBIOTA kit (CE-IVD - ARROW diagnostics) and second generation sequencing technologies (NGS on Illumina MiSeq platform). The control arm will provide for the characterization of the vaginal microbiota at the same timescales. Patients will be given a medical history questionnaire at T0 and T5m

NCT ID: NCT03913117 Recruiting - LSIL Clinical Trials

Study of Treatment for HPV16+ ASC-US or LSIL

PVX-6
Start date: July 10, 2023
Phase: Phase 1
Study type: Interventional

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

NCT ID: NCT03911076 Recruiting - ASC-US Clinical Trials

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

PVX-2
Start date: May 22, 2019
Phase: Phase 2
Study type: Interventional

- To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen - To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6

NCT ID: NCT03903952 Completed - Clinical trials for Human Papilloma Virus

Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?

Start date: May 1, 2014
Phase: N/A
Study type: Interventional

Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis. Mostly human papillomavirus (HPV) is responsible for this transition. Most of them are transient, but some infections become persistent and can progress into precancer and invasive cancer. In the process of progression to cancer; patients with cell cycle problems are thought to be at risk. In some studies, B12 and folate deficiency, which play a role in DNA synthesis and repair, have been shown to induce incorrect binding of uracil to DNA, leading to DNA breakage and repair disorder. Therefore, in this study, it has been aimed that the relation of presence of atypical squamous cells and HPV persistence with folate and vitamin B12 levels which effect on immune system.

NCT ID: NCT03409471 Recruiting - LSIL Clinical Trials

HPV Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study

Start date: May 4, 2018
Phase:
Study type: Observational

This study is a prospective observational study of human papillomavirus (HPV) testing using urine and self-collected vaginal samples for women who have atypical squamous cells of undetermined significance(ASCUS) or low grade squamous intraepithelial lesion(LSIL) on Pap test. Among women who are diagnosed with ASCUS and LSIL, HPV test is performed by collecting urine and self-collected vaginal sample in standardized condition before colposcopy, and evaluation will be performed as a primary screening test with cytology triage.

NCT ID: NCT03372395 Completed - Vaginal Infection Clinical Trials

Probiotic Implementation as Help in Solving Vaginal Infections

Start date: February 2015
Phase: Phase 2
Study type: Interventional

Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being. The aim of the study was to confirm that vaginal Lactobacilli long-lasting implementation in women with HPVinfections and concomitant bacterial vaginosis or vaginitis might be able to help in solving the viral infection, by re-establishing the original eubiosis.